The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and OAD Therapy
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 438 participants.
Also called NCT01676116
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 438 participants
- Sponsor
- Registry
-
NCT01676116 -
2012-000209-63
-
- Other papers using this trial's data
- EFFICACY AND SAFETY OF IDEGLIRA IN OLDER PATIENTS WITH TYPE 2 DIABETES
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Australia, France, Hungary, Slovakia
- Registry status
- Completed
Technical summary
Registry record NCT01676116. Randomized; no masking; primary purpose treatment. Start 2012-08-29 (actual); primary completion 2014-03-11 (actual). Results posted on 2018-07-09.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and OAD Therapy
- Acronym
- DUAL™ III
- Condition
- Diabetes
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- insulin degludec/liraglutide
- Intervention (Drug)
- liraglutide
- Intervention (Drug)
- exenatide
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct01676116- Content hash
1a73e75b14ce494fb96cc7796cd7997c17ed9677ffcc4d8998aca1806f2044f3